ReviewThe Journal of general virology2026
ORF2 of hepatitis E virus: genetic and antigenic variation across genotypes and implications for immunity, diagnostics and vaccine development.
Review in The Journal of general virology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatitis E virus (HEV) causes over 19 million infections annually, yet the molecular determinants governing its diverse clinical phenotypes and cross-genotype immunity remain incompletely synthesized. The ORF2 capsid protein is the sole structural component of the virion, the primary neutralizing antibody target and the basis for all commercial diagnostics and the only licensed vaccine (Hecolin®). While current literature often treats HEV as a monolithic antigenic entity, ORF2 sequences diverge by 15-25% across the eight recognized genotypes (GT1-GT8), with critical substitutions concentrated in the protruding (P) domain neutralizing epitopes. This comprehensive review integrates recent structural, virological and clinical data to evaluate the multidimensional impact of ORF2 variability. We highlight how the differential expression of three ORF2 isoforms (infectious ORF2i, secreted decoy ORF2g and cleaved ORF2c) complicates immune recognition. Furthermore, we critically analyse the functional consequences of P domain divergence, which results in 2-4-fold reduced cross-genotype neutralization by GT1-derived vaccines against the globally emerging GT3 and drives false-negative rates of 12-30% in commercial serological assays. Finally, we map ORF2 genetic signatures to distinct clinical phenotypes, including GT1-associated pregnancy mortality and GT3-driven chronicity in transplant recipients. By synthesizing these fragmented domains, this review identifies critical knowledge gaps, particularly concerning the zoonotic emergence of GT7/GT8 and provides a prioritized research roadmap for the development of true pan-genotype vaccines and universal diagnostic algorithms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.